Population-Based Cancer Survival in Canada and the United States by Socioeconomic Status: Findings from the CONCORD-2 Study.
Canada
United States
breast
cancer
cervix
colon
leukemia
liver
net
population-based
prostate
survival
Journal
Journal of registry management
ISSN: 1945-6123
Titre abrégé: J Registry Manag
Pays: United States
ID NLM: 9804163
Informations de publication
Date de publication:
2022
2022
Historique:
medline:
5
6
2023
pubmed:
1
4
2022
entrez:
1
6
2023
Statut:
ppublish
Résumé
Population-based cancer survival provides insight into the effectiveness of health systems to care for all residents with cancer, including those in marginalized groups. Using CONCORD-2 data, we estimated 5-year net survival among patients diagnosed 2004-2009 with one of 10 common cancers, and children diagnosed with acute lymphoblastic leukemia (ALL), by socioeconomic status (SES) quintile, age (0-14, 15-64, ≥65 years), and country (Canada or United States). In the lowest SES quintile, survival was higher among younger Canadian adults diagnosed with liver (23% vs 15%) and cervical (78% vs 68%) cancers and with leukemia (62% vs 56%), including children diagnosed with ALL (92% vs 86%); and higher among older Americans diagnosed with colon (62% vs 56%), female breast (87% vs 80%), and prostate (97% vs 85%) cancers. In the highest SES quintile, survival was higher among younger Americans diagnosed with stomach cancer (33% vs 27%) and younger Canadians diagnosed with liver cancer (31% vs 23%); and higher among older Americans diagnosed with stomach (27% vs 22%) and prostate (99% vs 92%) cancers. Among younger Canadian cancer patients in the lowest SES group, greater access to health care may have resulted in higher cancer survival, while higher screening prevalence and access to health insurance (Medicare) among older Americans during the period of this study may have resulted in higher survival for some screen-detected cancers. Higher survival in the highest SES group for stomach and liver may relate to treatment differences. Survival differences by age and SES between Canada and the United States may help inform cancer control strategies.
Sections du résumé
Background
UNASSIGNED
Population-based cancer survival provides insight into the effectiveness of health systems to care for all residents with cancer, including those in marginalized groups.
Methods
UNASSIGNED
Using CONCORD-2 data, we estimated 5-year net survival among patients diagnosed 2004-2009 with one of 10 common cancers, and children diagnosed with acute lymphoblastic leukemia (ALL), by socioeconomic status (SES) quintile, age (0-14, 15-64, ≥65 years), and country (Canada or United States).
Results
UNASSIGNED
In the lowest SES quintile, survival was higher among younger Canadian adults diagnosed with liver (23% vs 15%) and cervical (78% vs 68%) cancers and with leukemia (62% vs 56%), including children diagnosed with ALL (92% vs 86%); and higher among older Americans diagnosed with colon (62% vs 56%), female breast (87% vs 80%), and prostate (97% vs 85%) cancers. In the highest SES quintile, survival was higher among younger Americans diagnosed with stomach cancer (33% vs 27%) and younger Canadians diagnosed with liver cancer (31% vs 23%); and higher among older Americans diagnosed with stomach (27% vs 22%) and prostate (99% vs 92%) cancers.
Conclusions
UNASSIGNED
Among younger Canadian cancer patients in the lowest SES group, greater access to health care may have resulted in higher cancer survival, while higher screening prevalence and access to health insurance (Medicare) among older Americans during the period of this study may have resulted in higher survival for some screen-detected cancers. Higher survival in the highest SES group for stomach and liver may relate to treatment differences. Survival differences by age and SES between Canada and the United States may help inform cancer control strategies.
Identifiants
pubmed: 37260622
pii: jrm.2022.49.1.23
pmc: PMC10198415
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-33Informations de copyright
© 2022 National Cancer Registrars Association.
Références
Ann Epidemiol. 2003 Jan;13(1):32-41
pubmed: 12547483
CA Cancer J Clin. 2004 Jan-Feb;54(1):41-52
pubmed: 14974763
MMWR Morb Mortal Wkly Rep. 2012 Jan 27;61(3):41-5
pubmed: 22278157
Lancet. 2015 Mar 14;385(9972):977-1010
pubmed: 25467588
Cancer. 2017 Jul 1;123(13):2561-2569
pubmed: 28464280
Ann Intern Med. 2002 Jul 16;137(2):129-31
pubmed: 12118971
Cancer Causes Control. 2009 May;20(4):417-35
pubmed: 19002764
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):187-97
pubmed: 25417232
Ann Oncol. 2015 Mar;26(3):589-97
pubmed: 25527416
Prev Chronic Dis. 2016 Nov 17;13:E157
pubmed: 27854420
MMWR Suppl. 2011 Jan 14;60(1):35-7
pubmed: 21430617
Chronic Dis Can. 1998;19(3):112-30
pubmed: 9820835
Cancer Causes Control. 2009 Oct;20(8):1409-20
pubmed: 19496000
Cancer. 2010 Apr 1;116(7):1801-9
pubmed: 20143441
J Environ Public Health. 2017;2017:2819372
pubmed: 28408935
J Public Health Med. 2000 Sep;22(3):343-8
pubmed: 11077908
Public Health Rep. 2004 Mar-Apr;119(2):174-86
pubmed: 15192905
Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):736-742
pubmed: 28003180
Cancer. 2010 Feb 1;116(3):544-73
pubmed: 19998273
Int J Qual Health Care. 2011 Dec;23(6):611-20
pubmed: 21890706
PLoS One. 2012;7(7):e40917
pubmed: 22808283
Can J Public Health. 1998 Mar-Apr;89(2):102-4
pubmed: 9583250
Cancer. 2008 Aug 1;113(3):582-91
pubmed: 18613122
Lancet Oncol. 2008 Mar;9(3):222-31
pubmed: 18282806
Cancer J. 2010 Nov-Dec;16(6):614-21
pubmed: 21131794
Eur J Cancer. 2004 Feb;40(3):326-35
pubmed: 14746849
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):198-209
pubmed: 25417233
J Clin Oncol. 1999 Jul;17(7):2244-55
pubmed: 10561282
J Clin Oncol. 2014 Oct 1;32(28):3118-25
pubmed: 25092774
Eur J Cancer. 2004 Oct;40(15):2307-16
pubmed: 15454257
Ann Intern Med. 2002 Dec 3;137(11):915-6
pubmed: 12458992
Am J Public Health. 2000 Dec;90(12):1866-72
pubmed: 11111258
CMAJ. 2001 Feb 20;164(4):469-76
pubmed: 11233866
Biometrics. 2012 Mar;68(1):113-20
pubmed: 21689081
Cancer Causes Control. 2014 Jan;25(1):81-92
pubmed: 24178398
PLoS One. 2018 Jul 25;13(7):e0201034
pubmed: 30044829
Ann Intern Med. 2002 Sep 3;137(5 Part 1):344-6
pubmed: 12204019
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):236-43
pubmed: 25417237
Cancer Causes Control. 2009 Aug;20(6):989-1000
pubmed: 19199061
Cancer. 2017 Dec 15;123 Suppl 24:4982-4993
pubmed: 29205302
Cancer. 2010 Sep 1;116(17):4160-7
pubmed: 20681012
CMAJ. 2001 Jul 24;165(2):206-8
pubmed: 11501466
Curr Oncol. 2015 Apr;22(2):156-63
pubmed: 25908914
Am J Public Health. 1997 Jul;87(7):1156-63
pubmed: 9240106
J Registry Manag. 2020 Fall;47(3):102-112
pubmed: 34128915
Cancer J. 2017 Jul/Aug;23(4):246-253
pubmed: 28731949
Prev Chronic Dis. 2021 Jun 10;18:E59
pubmed: 34114543
J Viral Hepat. 2011 Jun;18(6):377-83
pubmed: 21143343
BMC Public Health. 2015 Dec 16;15:1240
pubmed: 27129577